Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data Neurocrine Plans to File the NDA During the First Half of 2019 PR Newswire SAN DIEGO, Feb. 14, 2018 SAN DIEGO , Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch on May 1, 2017 Total Revenue for the Fourth Quarter of 2017 was $94.5 Million and $161.6 Million for the Full-Year 2017 Elagolix PDUFA Action Date for Endometriosis in Q2 2018...

NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 13, 2018, at 5:00 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22281 . To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile. About...

Warning: Trading may expose you to risk of loss greater than your deposits and is only suitable for experienced clients who have sufficient financial means to bear such risk. The website only contains general information. They are not personal or investment advice nor a solicitation to buy or sell any financial instrument. Each investor must make their own judgement about the appropriateness of trading a financial instrument to their own financial, fiscal and legal situation.